IsomAb

Heart
#Cardiovascular disease #ESC Congress #IsomAb #Review

Landmark safety data support therapeutic angiogenesis

Safety evidence announced at the ESC Congress 2026 by Isomab has reinforced the potential of a new class of therapies designed to promote blood vessel growth as a disease-modifying approach for coronary artery disease (CAD).   The systematic review of clinical trial data evaluating growth factor approaches, spanning… Read More

#News

Heart in a box
#Biotech #Cardio #IsomAb

IsomAb appoints CEO to lead development of angina treatment 

Biotechnology company IsomAb has appointed Dr Philip Brainin as Chief Executive Officer as it looks to enter clinic with a treatment for chronic stable angina (CSA).  Brainin arrives with experience in cardiovascular medicine, clinical research, and venture investing across EU and US biotechnology companies. He has previously invested in… Read More

#News

Therapeutic antibodies
#IsomAb #Pfizer #Therapeutic Antibodies

Pfizer supports antibody for peripheral arterial disease

UK-based biotechnology company IsomAb has announced the nomination of a development candidate for peripheral arterial disease (PAD), therapeutic antibody ISM-001. ISM-001 is designed to neutralise VEGF-A165b, the anti-angiogenic VEGF-A splice isoform which acts as a brake on development of new blood vessels leading to chronic limb… Read More

#News